BRISTOL CAPITAL7 days ago I asked this question;
2. What is Bristol Capital doing for us ? It's been over a month and I've checked everywhere and can find NOTHING they have done for Telesta .And PLEASE don't tell me to have PATIENCE ! to-day we get an answer;
2015 BRISTOL CAPITAL SMART CONFERENCE
Presentation Time - Wednesday April 1st – 11:40 AM ET
Telesta is a late stage therapeutics company with near term commercial potential focused on a unique specialty drug (MCNA) for non-muscle invasive bladder cancer. The drug has completed a phase III study and the Company expects to file it biologics application license (BLA) with the FDA in Q2 of 2015.
Additional Highlights
- The US FDA has reviewed the Company’s clinical data and is supportive of a BLA filing with no additional trials.
- MCNA is a high margin biologic opportunity for Telesta that will be priced as a premium oncology product. The market size has been validated by an independent 3rd party and this market is significant.
- The Company has very strong intellectual property coverage with a patent term that would expire in 2031 along with secondary protection of 12 years with US market exclusivity for novel biologic.
- There has not been a new treatment for this type of cancer approved by the FDA since 1998.